Skip to main content

Core Laboratories Inc DE

For the period ended Dec 31, 2023. Filed Feb 15, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 15, 2024

CLB$9.03+2.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Item 16. Form 10-K Summary

Not applicable.

INDEX TO EXHIBITS

Exhibit No.Exhibit TitleIncorporated by Reference from theFollowing Documents
3.1Core Laboratories Inc. Certificate of IncorporationForm 8-K, May 1, 2023 (File No. 001-41695)
3.2Core Laboratories Inc. BylawsForm 8-K, May 1, 2023 (File No. 001-41695)
4.1Description of Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934Filed Herewith
10.1Core Laboratories N.V. 2020 Long-Term Incentive Plan (1)Appendix A to Definitive Proxy Statement dated March 20, 2020 for Annual Meeting of Shareholders (File No. 001-14273)
10.2Core Laboratories Inc. 2023 Non-Employee Director Stock Incentive Plan (as amended and restated effective as of June 28, 2023) (1)Appendix A to Definitive Proxy Statement dated April 28, 2023 for Annual Meeting of Shareholders (File No. 001-14273)
10.3Core Laboratories Supplemental Executive Retirement Plan effective as of January 1, 1998 (1)Form 10-K, March 31, 1998 (File No. 000-26710)
10.4Amendment to Core Laboratories Supplemental Executive Retirement Plan, effective July 29, 1999 (1)Form 10-Q, August 16, 1999 (File No. 001-14273)
10.5Amendment to Core Laboratories Supplemental Executive Retirement Plan, effective February 28, 2003 (1)Form 10-Q, May 15, 2003 (File No. 001-14273)
10.6Amendment to Core Laboratories Supplemental Executive Retirement Plan dated as of March 5, 2008 (1)Form 10-Q, May 12, 2008 (File No. 001-14273)
10.7Form of Restricted Share Award Program Agreement (1)Form 10-K, February 20, 2007 (File No. 001-14273)
10.8Form of Core Laboratories 2023 Non-Employee Director Restricted Share Award Program Agreement (1)Filed Herewith
10.9Form of Core Laboratories 2020 Performance Share Award Program Agreement (ROIC Based) (1)Filed Herewith
10.10Eighth Amended and Restated Credit Agreement, dated as of July 25, 2022, among Core Laboratories, N.V., and Core Laboratories (U.S.) Interests Holdings, Inc., and the lenders party thereto and Bank of America, N.A., as administrative agent and Wells Fargo Bank, N.A., as syndication agent and Comerica Bank, as documentation agent.Form 8-K, July 27, 2022 (File No. 001-14273)
10.11Amendment No. 1 to Eighth Amended and Restated Credit Agreement, dated as of April 28, 2023, among Core Laboratories, N.V., and Core Laboratories (U.S.) Interests Holdings, Inc. and the lenders party thereto and Bank of America, N.A., as administrative agentForm 8-K, May 1, 2023 (File No. 001-41695)
10.12Assumption and Reaffirmation Agreement, dated May 1, 2023, by and between Core Laboratories, Inc. and Bank of America, N.A.Form 8-K, May 1, 2023 (File No. 001-41695)
10.13Master Note Purchase Agreement, dated as of September 30, 2011Form 8-K, September 30, 2011 (File No. 001-14273)
10.14Amendment No. 2 to Master Note Purchase Agreement and Assumption Agreement, dated as of May 1, 2023Form 8-K, May 1, 2023 (File No. 001-41695)
10.15Amendment No. 2 to Note Purchase Agreement and Assumption Agreement, dated as of May 1, 2023Form 8-K, May 1, 2023 (File No. 001-41695)
10.16Note Purchase Agreement, dated as of May 4, 2023Form 8-K, May 4, 2023 (File No. 001-41695)
10.17Employment Agreement between Core Laboratories N.V. and Lawrence V. Bruno, dated March 1, 2019 (1)Form 8-K, March 6, 2019 (File No. 001-14273)
10.18Employment Agreement between Core Laboratories N.V. and Christopher S. Hill, dated March 1, 2019 (1)Form 8-K, March 6, 2019 (File No. 001-14273)
10.19Employment Agreement between Core Laboratories N.V. and Gwendolyn Y. Schreffler, dated March 1, 2019 (1)Form 10-K, February 8, 2021 (File No. 001-14273)
10.20Note Purchase Agreement, dated as of October 16, 2020.Form 8-K, October 16, 2020 (File No. 001-14273)
10.21Amendment to Employment Agreement, by and between Core Laboratories N.V. and Lawrence V. Bruno, dated March 1, 2020 (1).Form 8-K, March 5, 2020 (File No. 001-14273)
10.22Employment Agreement, by and between Core Laboratories N.V. and Mark D. Tattoli, dated October 18, 2021 (1)Form 8-K, October 19, 2021 (File No. 001-14273)
10.23Core Laboratories Inc. Incentive Compensation Recoupment PolicyFiled Herewith
10.24Amended and Restated Employment Agreement, by and between Core Laboratories Inc. and Lawrence V. Bruno, dated February 1, 2024 (1)Filed Herewith
10.25Amended and Restated Employment Agreement, by and between Core Laboratories Inc. and Christopher S. Hill, dated February 1, 2024 (1)Filed Herewith
10.26Amended and Restated Employment Agreement, by and between Core Laboratories Inc. and Gwendolyn Y. Schreffler, dated February 1, 2024 (1)Filed Herewith
10.27Amended and Restated Employment Agreement, by and between Core Laboratories Inc. and Mark D. Tattoli, dated February 1, 2024 (1)Filed Herewith
21.1Significant Subsidiaries of the RegistrantFiled Herewith
23.1Consent of KPMG LLPFiled Herewith
31.1Certification of Chief Executive Officer Pursuant to Rule 13a-14 of the Securities Exchange Act of 1934, As Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002Filed Herewith
31.2Certification of Chief Financial Officer Pursuant to Rule 13a-14 of the Securities Exchange Act of 1934, As Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002Filed Herewith
32.1Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002Filed Herewith
32.2Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002Filed Herewith
101.INSInline XBRL Instance Document- the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.Filed Herewith
101.SCHInline XBRL Taxonomy Extension Schema with Embedded Linkbases DocumentFiled Herewith
104Cover Page Interactive Data File (embedded within the Inline XBRL document).Filed Herewith

(1) Management contracts or compensatory plans or arrangements.

SIGNAT URES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CORE LABORATORIES INC.
Date:February 14, 2024By:/s/ LAWRENCE BRUNO
Lawrence Bruno
Chief Executive Officer, Chairman, President and Director

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities indicated, on the 9th day of February 2024.

SignatureTitle
/s/ LAWRENCE BRUNO/s/ CHRISTOPHER S. HILL
Lawrence BrunoChristopher S. Hill
Chief Executive Officer, Chairman,Senior Vice President and
President and DirectorChief Financial Officer
/s/ KEVIN G. DANIELS/s/ CURTIS ANASTASIO
Kevin G. DanielsCurtis Anastasio
Vice President, Treasurer andDirector
Chief Accounting Officer
/s/ MARTHA Z. CARNES/s/ HARVEY KLINGENSMITH
Martha Z. CarnesHarvey Klingensmith
DirectorDirector
/s/ KATHERINE A. MURRAY/s/ MICHAEL STRAUGHEN
Katherine A. MurrayMichael Straughen
DirectorDirector
/s/ KWAKU TEMENG
Kwaku Temeng
Director

Report of Independent Registered Public Accounting Firm

To the Shareholders and Board of Directors

Core Laboratories Inc.:

Opinion on the Consolidated Financial Statements

We have audited the accompanying consolidated balance sheets of Core Laboratories Inc. and subsidiaries (the Company) as of December 31, 2023 and 2022, the related consolidated statements of operations, comprehensive income (loss), changes in equity, and cash flows for each of the years in the three-year period ended December 31, 2023, and the related notes and financial statement schedule II (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2023, in conformity with U.S. generally accepted accounting principles.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control – Integrated Framework (2013)issued by the Committee of Sponsoring Organizations of the Treadway Commission, and our report dated February 14, 2024 expressed an unqualified opinion on the effectiveness of the Company’s internal control over financial reporting.

Basis for Opinion

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matter

The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of a critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

The impact of the Company’s organizational structure on its income tax provision

As discussed in note 1 to the consolidated financial statements, the Company completed its previously announced redomestication transaction and became domiciled in the United States on May 1, 2023. The Company has international operations requiring the evaluation of income taxes across many tax jurisdictions. As discussed in note 9, the Company recorded deferred tax assets, net of $69.2 million and deferred tax liabilities, net of $12.7 million as of December 31, 2023, and income tax expense of $4.2 million for the year then ended.

We identified the evaluation of the impact of the Company’s organizational structure on its income tax provision as a critical audit matter. Specifically, the redomestication transaction involved the evaluation of the identification, interpretation, and application of tax laws, which can be complex and subject to change, and its impact on the Company’s income tax provision required a high degree of auditor judgment and specialized skills and knowledge.

The following are the primary procedures we performed to address this critical audit matter. We evaluated the design and tested the operating effectiveness of certain internal controls related to the (1) execution of the redomestication transaction, (2)

identification, interpretation and application of tax laws and (3) accounting impact of the organizational structure related to the redomestication transaction. We inspected the Company’s legal entity organization chart to identify changes in structure. We evaluated the execution of the redomestication transaction and the application of tax laws related to the redomestication transaction and assessed current applicability by inspecting the Company’s correspondence and agreements with certain tax authorities, intercompany documentation, and advice and guidance from third parties. We involved income tax professionals with specialized skills and knowledge who assisted in (1) assessing the Company’s application of tax laws, including statutes, regulations, and case law and (2) evaluating the impact of the redomestication transaction on the tax provision.

/s/ KPMG LLP

We have served as the Company’s auditor since 2015.

Houston, Texas

February 14, 2024

Report of Independent Registered Public Accounting Firm

To the Shareholders and Board of Directors

Core Laboratories Inc.:

Opinion on Internal Control Over Financial Reporting

We have audited Core Laboratories Inc. and subsidiaries’ (the Company) internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control – Integrated Framework (2013)issued by the Committee of Sponsoring Organizations of the Treadway Commission. In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2023 and 2022, the related consolidated statements of operations, comprehensive income (loss), changes in equity, and cash flows for each of the years in the three-year period ended December 31, 2023, and the related notes and financial statement schedule II (collectively, the consolidated financial statements), and our report dated February 14, 2024 expressed an unqualified opinion on those consolidated financial statements.

Basis for Opinion

The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management's Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

Definition and Limitations of Internal Control Over Financial Reporting

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ KPMG LLP

Houston, Texas

February 14, 2024

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.